Core Insights - Astrana Health reported a remarkable year-on-year revenue growth of 99.7%, reaching $956 million, which exceeded Wall Street's estimates by 0.6% [1][5] - The company has shown strong annualized revenue growth of 47.7% over the last two years, indicating a recent acceleration in demand [1] - Astrana Health's sales have grown at a compounded annual growth rate of 33.3% over the last five years, outperforming the average healthcare company [2] Financial Performance - The company's free cash flow margin decreased to 0.8% from 6.6% in the same quarter last year, and the operating margin fell to 2% from 5.9% [4] - Astrana Health's full-year revenue guidance was lowered to $3.14 billion, which is 1.9% below previous estimates [4] - The GAAP profit for the company was reported at $0.01 per share, significantly below analysts' consensus estimates by 97.6% [5] Profitability Trends - Astrana Health's operating margin has decreased by 14 percentage points over the last five years, indicating rising expenses that could not be passed onto customers [8] - The operating margin for Q3 was 2%, down 3.9 percentage points year on year, reflecting less efficiency due to faster-growing expenses compared to revenue [9] - Earnings per share (EPS) declined by 27.1% annually over the last five years, despite revenue growth, suggesting reduced profitability on a per-share basis [10] Market Expectations - Analysts project a revenue growth of 37.2% over the next 12 months, indicating a slowdown compared to the previous two years but still reflecting confidence in the company's products and services [6] - Wall Street expects Astrana Health's full-year EPS to grow 877% over the next 12 months, despite the current low EPS of $0.01 [12]

Third Quarter 2025 Earnings Supplement November 2025 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include any statements about the Company's business, financial condition, operating results, plans, objectives, expectations and intentions, expansion plans, estimates of our total addressable market, our ...

Financial Data and Key Metrics Changes - Total members increased by 53% year over year to 831,000, with revenue growing by 49% year over year to $68 million [4][22] - GAAP gross margin reached 66%, while non-GAAP gross margin was at 68%, both showing significant improvement from the previous year [4][23] - The net loss was reduced to $3 million compared to $9 million in Q3 2024, marking a notable improvement in financial performance [4][24] - For the first time, the company achieved a positive adjusted EBITDA of $2 million, compared to a loss of $5 million in Q3 2024 [4][24] Business Line Data and Key Metrics Changes - The GLP-1 CareTrack program has been a significant driver of growth, reflecting strong demand and multi-condition adoption [11][22] - The company reported that 75% of new customers opted for multiple Omada programs, indicating the appeal of its integrated multi-condition platform [12] Market Data and Key Metrics Changes - The company has seen healthy activity in the current selling season, with early sales traction through a large new channel partner, representing an estimated 180,000 individuals [11] - The demand for GLP-1 offerings has been a key factor in the company's growth, with significant interest from employers and health plans [6][22] Company Strategy and Development Direction - The company plans to invest in GLP-1 offerings and AI technologies, aiming to enhance its solutions and widen its competitive moat [9][25] - The strategic focus is on delivering integrated care that combines clinical services with behavioral support, addressing the complexities of medication management [6][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the potential for growth in 2026 and beyond, driven by innovations in GLP-1 therapies and AI integration [9][10] - The company aims to achieve sustained profitability while continuing to invest in key areas that can enhance its service offerings [25] Other Important Information - The company published its 30th peer-reviewed manuscript, demonstrating the effectiveness of its programs in reducing medical costs and improving health outcomes [18][19] - The company ended Q3 with cash and cash equivalents of $199 million, down from $223 million in Q2 2025, primarily due to debt repayment [25] Q&A Session Summary Question: Can you discuss the new GLP-1 prescribing initiative? - Management highlighted that the new prescribing capability will be integrated within the Omada Care program, allowing members to fulfill prescriptions at their chosen pharmacy [30][31] Question: What investments are needed to launch this new offering? - Management indicated that investments will be required across engineering, product, sales, and marketing to support the new prescribing functionality [39] Question: How is the selling season progressing? - Management noted that they are seeing strong multi-product penetration and healthy activity in the selling season, with double-digit volume deal growth year over year [40] Question: How does GLP-1 drive growth in the overall portfolio? - Management stated that while GLP-1 CareTrack contributes to growth, the majority of new members still come from non-GLP-1 offerings, reflecting a successful multi-product sales strategy [76]

Financial Performance - Revenue reached $479.5 million, reflecting an 8% sequential increase, driven by new launches in Performance Suite and Specialty Tech & Services[6] - Adjusted EBITDA was $39.0 million, a 23% year-over-year growth[6] - The company narrowed its revenue outlook for 2026 to between $1.87 billion and $1.88 billion[6] - Adjusted EBITDA outlook narrowed to between $144 million and $154 million[6] Capital Allocation - Evolent Health had $116.7 million in cash and cash equivalents as of September 30, 2025, with $47.5 million in revolver availability[6] - The company issued $166.8 million of 4.50% 2031 Notes and repaid $167.4 million of 2025 Notes[6] - Evolent repurchased 4.4 million shares of common stock for $40.0 million[6] - Exchanged $175.0 million of Series A Preferred Stock for second lien term loan on similar terms, with interest now tax deductible[6] - Period-end net leverage was 6.7x on LTM Adjusted EBITDA of $136.0 million[6] Business Growth - Announced two new revenue arrangements, one in the Performance Suite and one in the Technology and Services Suite, bringing YTD total to 13, forecasting approximately $2.5 billion for 2026[6]

Core Insights - Evolent Health, Inc. reported strong financial results for Q3 2025, achieving revenue of $479.5 million, which is a decrease from $621.4 million in Q3 2024, but the company is optimistic about future growth with a preliminary revenue forecast of $2.5 billion for 2026 [2][9][14] - The company added two new customer agreements in the quarter, bringing the total for the year to thirteen, and expects to generate over $750 million in new annualized revenue in 2026 [3][4] - Evolent's Adjusted EBITDA for Q3 2025 was $39.0 million, up from $31.8 million in Q3 2024, indicating improved operational efficiency [2][11] Financial Performance - Revenue for the three months ended September 30, 2025, was $479.5 million, down from $621.4 million in the same period last year [9] - The net loss attributable to common shareholders was $26.9 million, an improvement from a loss of $31.2 million in Q3 2024, resulting in a net loss margin of 5.6% compared to 5.0% [9][10] - Adjusted EBITDA increased to $39.0 million with an adjusted EBITDA margin of 8.1%, up from 5.1% in the prior year [2][11] Customer and Market Developments - Evolent signed two new revenue agreements in Q3 2025, contributing to a total of thirteen new contracts for the year [3][4] - A new partnership with a large regional Blues plan will implement Evolent's Performance Suite for Oncology, covering over 650,000 members [5] - The company continues to experience strong demand for its complex specialty care solutions due to rising medical costs impacting health plans [2] Leadership Changes - Mario Ramos has been appointed as the new Chief Financial Officer effective January 1, 2026, bringing extensive experience from CVS Health and WellBe Senior Medical [6][7] - John Johnson will transition to the role of Chief Strategy Officer, and Emily Rafferty will become Executive Vice President, Customer Success [7] Business Outlook - For Q4 2025, Evolent expects revenue to be in the range of $462 million to $472 million, with adjusted EBITDA projected between $30 million and $40 million [13] - The full-year revenue forecast for 2025 is approximately $1.87 billion to $1.88 billion, with adjusted EBITDA expected to be between $144 million and $154 million [14][15]

Core Insights - Astrana Health, Inc. reported strong third-quarter results for 2025, with significant revenue growth and successful integration of Prospect Health [2][9][10] - The company is focused on enhancing its care delivery platform and maintaining strong clinical and cost performance despite some delays in full-risk contract transitions [2][9] Financial Highlights for Q3 2025 - Total revenue reached $956.0 million, a 100% increase from $478.7 million in Q3 2024 [9][10] - Adjusted EBITDA was $68.5 million, up 52% from $45.2 million in the same quarter last year [10][22] - Net income attributable to Astrana was $0.4 million, with diluted earnings per share of $0.01 [10][20] Financial Highlights for Nine Months Ended September 30, 2025 - Total revenue for the nine months was $2,231.2 million, a 63% increase from $1,369.3 million [10][19] - Adjusted EBITDA for the nine months was $153.0 million, up 13% from $135.3 million [10][22] - Net income attributable to Astrana for the nine months was $16.5 million, with diluted earnings per share of $0.33 [10][20] Recent Operating Highlights - Care Partners revenue was $897.7 million, a 97% increase from $455.8 million in Q3 2024 [10][19] - The company successfully closed the acquisition of Prospect Health, which exceeded performance expectations [9][10] - Astrana announced a strategic partnership with Intermountain Health to enhance care access and improve patient outcomes in southern Nevada [10][19] Guidance for 2025 - Updated guidance for total revenue is projected between $3.1 billion and $3.18 billion, with Adjusted EBITDA expected between $200 million and $210 million [11][29] - The guidance reflects adjustments for full-risk contract delays unrelated to core performance [9][11] Cash Flow and Balance Sheet Highlights - Cash and cash equivalents as of September 30, 2025, were $462.2 million, up from $288.5 million at the end of 2024 [17][21] - Total assets increased to $2,237.2 million from $1,354.9 million at the end of 2024 [17][18] - Total liabilities rose to $1,682.5 million from $840.7 million at the end of 2024 [17][18]

Group 1: Company Analysis - Box (BOX) has a trailing 12-month GAAP operating margin of 6.1% and is known as the "Content Cloud" for managing unstructured business data [2] - Danaher (DHR) has a trailing 12-month GAAP operating margin of 19% and operates as a global science and technology company providing specialized equipment and services [5] - Universal Health Services (UHS) has a trailing 12-month GAAP operating margin of 11.5% and operates acute care hospitals and behavioral health facilities across multiple countries [10] Group 2: Financial Metrics - Box is currently trading at $31.08 per share, with a forward price-to-sales ratio of 3.9x [4] - Danaher is trading at $211.03 per share, with a forward P/E ratio of 26.2x [7] - Universal Health Services has shown an average billings growth of 10% over the last year, with projected sales growth of 7.9% for the next 12 months [8] Group 3: Performance Concerns - Box is facing challenges in maintaining growth and competition, which may limit its future potential [1] - Danaher is viewed with hesitation due to its high valuation compared to potential opportunities [6][7] - Universal Health Services has seen a decrease in efficiency, with its adjusted operating margin falling by 7.9 percentage points over the last five years [9]

Core Insights - Healthcare Services Group, Inc. (HCSG) provides management, administrative, and operational services to the healthcare industry, focusing on housekeeping, laundry, and dietary services for various healthcare facilities [1] Performance Summary - HCSG has shown a significant monthly gain of approximately 12.44%, reflecting strong investor confidence and positive market sentiment [2][6] - Despite a slight decline of 3.33% over the last 10 days, this short-term correction may present a strategic entry point for investors [3][6] Growth Potential - HCSG has a robust stock price growth potential of 22.29%, indicating significant room for appreciation and potential substantial returns for growth-oriented investors [4][6] - The company boasts a perfect Piotroski Score of 9, indicating strong financial health and operational efficiency, which reassures investors about its fundamental soundness [5][6]

Core Insights - Aveanna Healthcare reported $621.94 million in revenue for the quarter ended September 2025, marking a year-over-year increase of 22.2% and an EPS of $0.15 compared to $0.02 a year ago, exceeding the Zacks Consensus Estimate of $0 million and showing an EPS surprise of +87.5% [1] Financial Performance Metrics - Aveanna's shares have returned +2.9% over the past month, outperforming the Zacks S&P 500 composite's +1.3% change, with a Zacks Rank 1 (Strong Buy) indicating potential for further outperformance in the near term [3] - Key metrics for Aveanna include: - Hours - PDS: 11,822.00 hours versus 11,102.22 hours estimated by two analysts on average - Revenue rate - MS: $495.43 million versus $489.43 million estimated by two analysts on average - Unique patients served (UPS) - MS: 91 versus the two-analyst average estimate of 92 - Revenue rate - PDS: $43.51 million compared to the $42.62 million average estimate based on two analysts - Revenue - PDS: $514.43 million versus the three-analyst average estimate of $473.17 million, representing a year-over-year change of +25.6% - Revenue - MS: $45.08 million versus the three-analyst average estimate of $44.63 million, representing a year-over-year change of -0.5% - Revenue - HHH: $62.43 million compared to the $59.35 million average estimate based on three analysts, representing a change of +15.3% year over year [5]

Financial Data and Key Metrics Changes - Privia Health reported a 27.1% year-over-year increase in practice collections, reaching $940.4 million in Q3 2025 [10] - Adjusted EBITDA increased by 61.6% to $38.2 million, with an EBITDA margin of 30.5%, reflecting a 720 basis point improvement year-over-year [5][10] - For the first nine months of 2025, practice collections rose 19.6% to $2.6 billion, while adjusted EBITDA grew 43.5% to $94.1 million [11] Business Line Data and Key Metrics Changes - Implemented provider growth was 13.1% year-over-year, reaching 5,250 providers [10] - Value-based attribution growth increased by 12.8% year-over-year, contributing to strong practice collections [4] - The total attributed lives increased by nearly 13% from the previous year, with commercial attributed lives up over 12% to 864,000 [6][7] Market Data and Key Metrics Changes - Privia managed over $2.5 billion in medical spend across nine ACOs in the Medicare Shared Savings Program (MSSP) for 2024, achieving a savings rate of 9.4%, up from 8.2% in 2023 [9] - Total shared savings reached $234.1 million, a 32.6% increase from the previous year, with gross shared savings of $160.1 million, reflecting a 36% increase over 2023 [9] Company Strategy and Development Direction - The company is focused on expanding its national footprint and enhancing its value-based care model, with an acquisition of an ACO business from Elevance Health for $100 million expected to close by year-end 2025 [5][6] - The acquisition is anticipated to add over 120,000 value-based care attributed lives and enhance operational synergies [5] - The company aims to maintain a diversified value-based care organization to build scale and profitability without reliance on any single contract [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued strong performance and momentum into 2026, with expectations for practice collections to grow 17.1% and care margin to increase by 13.2% [12] - The company plans to remain disciplined in its approach to business development and acquisitions, leveraging its strong cash position of over $400 million [39] - Management highlighted the importance of aligning interests among payers, providers, and the company for sustainable long-term growth [85] Other Important Information - The company has a balanced and diversified value-based care organization serving over 1.4 million patients through more than 100 commercial and government programs [6] - Pro forma free cash flow for the year-to-date was $104.4 million, with expectations to end the year with at least $410 million in cash [11] Q&A Session Summary Question: Future guidance on MSSP performance - Management indicated that strong results from 2024 will be factored into future planning, maintaining consistency in guidance updates based on performance relative to benchmarks [16][17] Question: Core business performance into Q4 - Management noted strong trends and momentum heading into Q4, emphasizing a focus on annual results rather than quarterly guidance [19][20] Question: Factors influencing fee-for-service growth - Management attributed strong fee-for-service growth to broad-based utilization trends and the addition of new markets, including Arizona [22][24] Question: Synergy opportunities with Evelyn Health ACO - Management discussed the potential for significant synergies and improvements in shared savings rates over time, emphasizing a gradual integration process [26][28] Question: Evolution of relationships with payers - Management highlighted ongoing discussions with payers, leveraging strong performance to negotiate favorable contracts across various payer classes [45][47] Question: Impact of new legislation on Medicaid - Management expressed that the impact of new legislation on Medicaid is expected to be minimal, given the small percentage of collections from this segment [76][77] Question: Ancillary services growth opportunities - Management indicated a focus on expanding ancillary services as the company builds density in new markets, enhancing overall cost management [60][62] Question: Future risk in MA contracts - Management reiterated a cautious approach to capitated MA contracts, emphasizing the importance of shared risk models for sustainable growth [32][34]